# Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

> **NCT00116168** · PHASE1 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 29 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** MEDI-528 0.3 mg/kg
- **BIOLOGICAL:** MEDI-528 1 mg/kg
- **BIOLOGICAL:** MEDI-528 3 mg/kg
- **BIOLOGICAL:** MEDI-528 9 mg/kg

## Key facts

- **NCT ID:** NCT00116168
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-04
- **Final completion:** 2006-07
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2013-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116168, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00116168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*